Catherine Hambleton Davis

Dr. Catherine Hambleton Davis


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in The American Journal of Surgery
Verified
Journal Article
Closed access
EHEunice Y. Huang
Eunice Y. Huang
SKSamantha Knight
Samantha Knight
CGCamila Roginski Guetter
Camila Roginski Guetter
CDCatherine Hambleton Davis
Catherine Hambleton Davis
MMMecker G Möller
Mecker G Möller
MCMarie Crandall
Marie Crandall

1 March 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
CDCatherine Hambleton Davis
Catherine Hambleton Davis
BSBeverly A. Shirkey
Beverly A. Shirkey
LMLinda W Moore
Linda W Moore
TGTanmay Gaglani
Tanmay Gaglani
XDXianglin L. Du
Xianglin L. Du
MCMarianne V. Cusick
Marianne V. Cusick

1 October 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
CDCatherine Hambleton Davis
Catherine Hambleton Davis
JHJason Ho
Jason Ho
RSRyan Stephenson
Ryan Stephenson
DADavid A. August
David A. August
HGHeather Gee
Heather Gee
Adam C. BergerAdam C. Berger
Adam C. Berger
PURPOSE: Many cancer centers engage in multidisciplinary tumor board meetings to determine the optimal approach to complex cancer care. With the onset of the COVID-19 pandemic, many institutions changed the format of these meetings from in-person to virtual. The aim of this study was to determine if the change to a virtual meeting format had an impact on attendance and cases presented. METHODS: Tumor board records were analyzed to obtain attendance and case presentation information at a National Cancer Institute–designated Comprehensive Cancer Center. Twelve-month in-person tumor board data were compared with 12-month virtual tumor board data to assess for difference in attendance and case presentation patterns. RESULTS: Seven separate weekly tumor board meetings at the beginning of the study (breast, GI, gynecology, liver, lung, melanoma, and urology) were expanded to nine meetings on the virtual platform (+endocrine and pancreas). Overall attendance increased by 46% on the virtual platform compared with in-person meetings (4,030 virtual attendances v 2,753 in-person, P < .001). Increased attendance was present across all specialties on the virtual platform. In addition, the number of patient cases discussed increased from 2,127 in in-person meeting to 2,656 on the virtual platform (a 20% increase, P < .001). CONCLUSION: A significant increase was observed in overall tumor board attendance and in case presentations per meeting, requiring the expansion of additional weekly meetings. Furthermore, in a major cancer center with multiple community affiliates, virtual tumor boards may encourage increased participation from remote sites with the benefit of obtaining expert specialist advice as compared with geographically challenging in-person meetings.

1 July 2019 in Surgery
Verified
Journal Article
Closed access
HLHeather A. Lillemoe
Heather A. Lillemoe
RMRebecca K. Marcus
Rebecca K. Marcus
RDRyan W. Day
Ryan W. Day
BKBradford Kim
Bradford Kim
NNNisha Narula
Nisha Narula
TAThomas A. Aloia
Thomas A. Aloia

1 December 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
HLHeather A. Lillemoe
Heather A. Lillemoe
RMRebecca K. Marcus
Rebecca K. Marcus
BKBradford Kim
Bradford Kim
NNNisha Narula
Nisha Narula
CDCatherine Hambleton Davis
Catherine Hambleton Davis
TAThomas A. Aloia
Thomas A. Aloia

28 August 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
BKBradford Kim
Bradford Kim
RDR. W. Day
R. W. Day
CDCatherine Hambleton Davis
Catherine Hambleton Davis
NNN. Narula
N. Narula
MKM. H. Kroll
M. H. Kroll
TAT. A. Aloia
T. A. Aloia
Essentials The risk for venous thromboembolism after liver surgery remains high in the modern era. We evaluated the safety/efficacy of extended anticoagulation in liver surgery. This protocol reports zero venous thromboembolism events in 124 liver surgery patients. Extended anticoagulation after oncologic liver surgery is safe and effective. Summary Background The incidence of venous thromboembolism (VTE) after liver surgery remains high. Objective To evaluate the safety and efficacy of extended pharmacologic thromboprophylaxis after liver surgery for the prevention of VTE. Patient/Methods From August 2013 to April 2015, 124 patients who underwent liver resection for malignancy were placed on an extended pharmacologic thromboprophylaxis protocol. Intraoperative VTE prophylaxis included thromboembolic deterrent hoses and sequential compression devices. Once hemostasis had been ensured following hepatectomy, daily anticoagulant VTE prophylaxis was initiated for the duration of hospitalization. After hospital discharge, the large majority of patients (114, 91.9%) continued to receive anticoagulant thromboprophylaxis (enoxaparin) to complete a total course of 14 days after minor/minimally invasive hepatectomy or 28 days after major hepatectomy or a history of VTE. Results The cohort included 39 (31.2%) major hepatectomies and 38 (31.5%) minor/minimally invasive approaches. The intraoperative, postoperative and overall transfusion rates were 5.6%, 8.1%, and 10.5%, respectively. Pharmacologic thromboprophylaxis was started on postoperative day (POD) 0 for 40 (32.3%) patients and on POD 1 for 84 (67.7%) patients. During 90 days of follow‐up, no postoperative symptomatic deep vein thrombosis or pulmonary embolic events were diagnosed. Standard‐protocol computed tomography scans of the chest, abdomen and pelvis that were obtained for 112 (90.3%) study patients showed no pulmonary emboli, or other thoracic, splanchnic or ileofemoral vein thromboses. Two (1.6%) patients had minor bleeding events that resolved after discontinuation of enoxaparin, requiring neither blood transfusion nor reoperation. The severe complication rate was 5.6%, with no 90‐day mortalities. Conclusions These preliminary data suggest that extended pharmacologic thromboprophylaxis for liver surgery patients is safe and effective.